Tag: ADC manufacturing
Lonza – Celebrating 10 Years as ADC Manufacturing Pioneer
By leveraging the company's experience in biopharmaceuticals and small molecule drug process development and scale-up, Lonza has been successful in manufacturing antibody-drug conjugates, a...
Contract Manufacturing of Antibody-drug Conjugates – A Growing Market
The demand for manufacturing capacity of antibody-drug conjugates (ADCs), which includes a highly potent cytotoxic drug linked to a monoclonal antibody and have shown to...
Strategic Collaboration Between CMC Biologics and IDT Biologika to Manufacture Antibody...
Denmark-based CMC Biologics, a company involved in the clinical and commercial manufacturing of monoclonal antibodies and other therapeutic proteins, and IDT Biologika, a privately-held...
Q&A – an Interview with Lonza’s Laurent Ducry
Antibody-drug Conjugates or ADCs are among the most exciting drug developments of the last decade. The combination of potent, small molecule drugs with the...
CPhI Worldwide 2015, Antibody-drug Conjugates and Market Progression
Ahead of CPhI Worldwide 2015, CPhI expert panelist, Vivek Sharma, CEO of Pharma Solutions at Piramal, analyses the challenges in developing and manufacturing of...
Consideration for the Safe and Effective Manufacturing of Antibody-drug Conjugates
Antibody drug conjugates are an emerging class of biotherapeutics which require unique supporting infrastructure to meet bio/ pharmaceutical industry standards for safe, effective and reliable manufacturing. These highly potent biopharmaceuticals present a series of unique manufacturing challenges driven by their potency and raw material supply chain. Facility design must take into consideration these manufacturing challenges to insure employee safety and robust process performance. The concepts addressed in this article convey the experience gained by Lonza during our years working with this class of biotherapeutics.
